Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

RIPK Inhibitors

Receptor-interacting serine/threonine kinases (RIPKs) are a family of kinases that play a critical role in regulating cell death, inflammation, and immune responses. RIPKs, particularly RIPK1 and RIPK3, are best known for their involvement in necroptosis, a form of programmed necrosis. They function by interacting with various receptors, such as tumor necrosis factor receptors (TNFRs), and are activated through complex signaling cascades involving ubiquitination and phosphorylation. Upon activation, RIPKs can either promote cell survival and inflammation via activation of NF-κB and MAPK pathways or induce cell death through the formation of a necrosome complex, particularly in the presence of caspase inhibition. Their ability to switch between pro-survival and pro-death pathways is critical for maintaining cellular homeostasis and responding to cellular stress and damage.

RIPK (Receptor-interacting serine/threonine kinase) inhibitors are a group of chemical compounds designed to modulate the activity of receptor-interacting serine/threonine kinases, a family of kinases crucial in various cellular signaling pathways. These kinases, particularly RIPK1, RIPK2, and RIPK3, are involved in the regulation of cell death, inflammation, and immune responses. RIPK inhibitors operate by targeting these kinases, thereby modulating their kinase activity. The development of RIPK inhibitors has advanced our understanding of kinase signaling pathways. By inhibiting specific kinases, these compounds help elucidate the roles of RIPKs in various cellular processes. For example, the inhibition of RIPK1 can provide insights into its role in NF-κB activation, a crucial factor in the inflammatory response and cell survival.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

SB 202190

152121-30-7sc-202334
sc-202334A
sc-202334B
1 mg
5 mg
25 mg
$30.00
$125.00
$445.00
45
(1)

SB203580 targets RIPK (Receptor-interacting serine/threonine kinase) kinase activity, disrupting its signaling cascades and dampening the pro-inflammatory responses driven by RIPK (Receptor-interacting serine/threonine kinase), making it a potential anti-inflammatory agent.

AP 24534

943319-70-8sc-362710
sc-362710A
10 mg
50 mg
$172.00
$964.00
2
(1)

Originally developed as a cancer drug, ponatinib has been shown to inhibit RIPK1 and RIPK3, thereby affecting necroptosis.

MCC950 sodium salt

256373-96-3sc-505904
sc-505904A
sc-505904B
sc-505904C
5 mg
10 mg
50 mg
100 mg
$112.00
$194.00
$871.00
$1538.00
3
(0)

MCC950 specifically inhibits RIPK (Receptor-interacting serine/threonine kinase)-mediated inflammasome activation by interfering with its kinase activity, offering potential therapeutic value in inflammatory and autoinflammatory diseases.

Dabrafenib

1195765-45-7sc-364477
sc-364477A
sc-364477B
sc-364477C
sc-364477D
5 mg
25 mg
50 mg
100 mg
10 g
$138.00
$255.00
$273.00
$403.00
$12240.00
6
(1)

Dabrafenib inhibits RIPK (Receptor-interacting serine/threonine kinase), possibly by targeting its kinase activity, which may have implications for attenuating inflammatory signaling pathways driven by RIPK (Receptor-interacting serine/threonine kinase) activation.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Originally a kinase inhibitor used in cancer, sorafenib has been observed to inhibit RIPK1 and RIPK3 at higher concentrations.

UNC 0224

1197196-48-7sc-362816
sc-362816A
10 mg
50 mg
$194.00
$816.00
(0)

URMC-099 inhibits RIPK (Receptor-interacting serine/threonine kinase) kinase activity, which might mitigate the excessive inflammation associated with RIPK (Receptor-interacting serine/threonine kinase) activation, holding promise for interventions in inflammatory diseases.